Provided by Tiger Fintech (Singapore) Pte. Ltd.

Adverum Biotechnologies

4.58
+0.07501.67%
Volume:32.89K
Turnover:150.12K
Market Cap:95.17M
PE:-0.83
High:4.67
Open:4.51
Low:4.51
Close:4.50
Loading ...

Adverum Biotechnologies Price Target Maintained With a $30.00/Share by HC Wainwright & Co.

Dow Jones
·
19 Nov 2024

Adverum Biotechnologies Advances Ixo-vec Gene Therapy Trials

TIPRANKS
·
19 Nov 2024

Buy Rating on Adverum Biotechnologies: Ixo-vec’s Promising Potential in Transforming Wet AMD Treatment

TIPRANKS
·
19 Nov 2024

Adverum Reports Positive Ixo-vec Data for Wet Age-Related Macular Degeneration; Shares Rise Pre-Bell

MT Newswires Live
·
18 Nov 2024

Adverum Biotechnologies Inc: Expects to Be Able to Fund Operations Into Second Half of 2025

THOMSON REUTERS
·
18 Nov 2024

Adverum Biotechnologies Inc: 6E10 Dose in Luna Maintains Visual and Anatomic Endpoints

THOMSON REUTERS
·
18 Nov 2024

Adverum Biotechnologies Announces Positive 52-Week LUNA and 4-Year OPTIC Results, and Provides Key Pivotal Program Design Elements

GlobeNewswire
·
18 Nov 2024

Adverum Biotechnologies Announces Webcast to Report 52-Week LUNA Phase 2 Clinical Data and 4-Year OPTIC Clinical Data, and to Provide Key Pivotal Program Design Elements

GlobeNewswire
·
16 Nov 2024

Adverum Biotechnologies Inc expected to post a loss of $1.31 a share - Earnings Preview

Reuters
·
06 Nov 2024

Adverum Biotechnologies price target lowered to $10 from $12 at RBC Capital

TIPRANKS
·
05 Nov 2024

Oppenheimer Sticks to Their Buy Rating for Adverum Biotechnologies (ADVM)

TIPRANKS
·
05 Nov 2024

Adverum Biotechnologies Advances in Gene Therapy Development

TIPRANKS
·
05 Nov 2024

Adverum Biotechnologies (ADVM) Gets a Buy from TD Cowen

TIPRANKS
·
05 Nov 2024

Adverum Biotechnologies (ADVM) Reports Q3 Loss, Tops Revenue Estimates

Zacks
·
05 Nov 2024

Adverum Biotechnologies reports Q3 EPS ($1.30), consensus ($1.31)

TIPRANKS
·
05 Nov 2024

Adverum Biotechnologies: Q3 Earnings Snapshot

Associated Press Finance
·
05 Nov 2024